5-Year results of robotic female AUS implantation: our single-center series of 42 patients.

IF 2.6 4区 医学 Q2 UROLOGY & NEPHROLOGY
Therapeutic Advances in Urology Pub Date : 2025-06-09 eCollection Date: 2025-01-01 DOI:10.1177/17562872251342699
Alexandre Dubois, Claire Richard, Camille Haudebert, Juan Penafiel, Caroline Voiry, Magali Jezequel, Emmanuelle Samson, Lucas Freton, Andrea Manunta, Juliette Hascoet, Benoit Peyronnet
{"title":"5-Year results of robotic female AUS implantation: our single-center series of 42 patients.","authors":"Alexandre Dubois, Claire Richard, Camille Haudebert, Juan Penafiel, Caroline Voiry, Magali Jezequel, Emmanuelle Samson, Lucas Freton, Andrea Manunta, Juliette Hascoet, Benoit Peyronnet","doi":"10.1177/17562872251342699","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In recent years, several preliminary reports have suggested that the robot-assisted approach may decrease the surgical morbidity of artificial urinary sphincter (AUS) implantation in female patients with stress urinary incontinence (SUI). However, for now, only short-term outcomes have been reported. The present study aimed to report the 5-year outcomes of robot-assisted AUS implantation in female patients.</p><p><strong>Patients and methods: </strong>All female patients who underwent a robot-assisted AUS implantation between January 2014 and September 2019 at a single academic center were included in a retrospective study. All robot-assisted female AUS implantations performed after September 2019 were excluded to ensure a 5-year minimum follow-up duration. The indication for AUS implantation was SUI due to intrinsic sphincter deficiency. The primary endpoint was the explantation-free survival and revision-free survival.</p><p><strong>Results: </strong>Forty-two patients were included. The median age was 66 years (28-84), and 83.8% of the patients had a history of previous anti-incontinence procedure. After a median follow-up of 64 months (16-110), 8 patients were lost to follow-up before the 5-year time point. The 5-year estimated revision-free survival was 89.2 and the 5-year estimated explantation-free survival was 88%. Five AUS explantations were needed (11.9%), and six revisions were required (14.3%). The median time to explantation was 14 months. Four explantations (80%) occurred within the first 18 months, and all of them within the first 27 months. Thirty patients (71.42%) had a complete or improved continence with a complete continence rate of 59.52% and an improved continence rate of 11.9%. There were 10 intraoperative complications (23.8%): 5 bladder injuries and 5 vaginal injuries. Thirteen patients had postoperative complications (30.9%), but only two were Clavien grade ⩾3.</p><p><strong>Conclusion: </strong>The 5-year outcomes of robot-assisted AUS implantation seem to confirm the promising short-term outcomes that have been reported so far, although revision rates increased with time, which warrants further investigation.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"17 ","pages":"17562872251342699"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149613/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562872251342699","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: In recent years, several preliminary reports have suggested that the robot-assisted approach may decrease the surgical morbidity of artificial urinary sphincter (AUS) implantation in female patients with stress urinary incontinence (SUI). However, for now, only short-term outcomes have been reported. The present study aimed to report the 5-year outcomes of robot-assisted AUS implantation in female patients.

Patients and methods: All female patients who underwent a robot-assisted AUS implantation between January 2014 and September 2019 at a single academic center were included in a retrospective study. All robot-assisted female AUS implantations performed after September 2019 were excluded to ensure a 5-year minimum follow-up duration. The indication for AUS implantation was SUI due to intrinsic sphincter deficiency. The primary endpoint was the explantation-free survival and revision-free survival.

Results: Forty-two patients were included. The median age was 66 years (28-84), and 83.8% of the patients had a history of previous anti-incontinence procedure. After a median follow-up of 64 months (16-110), 8 patients were lost to follow-up before the 5-year time point. The 5-year estimated revision-free survival was 89.2 and the 5-year estimated explantation-free survival was 88%. Five AUS explantations were needed (11.9%), and six revisions were required (14.3%). The median time to explantation was 14 months. Four explantations (80%) occurred within the first 18 months, and all of them within the first 27 months. Thirty patients (71.42%) had a complete or improved continence with a complete continence rate of 59.52% and an improved continence rate of 11.9%. There were 10 intraoperative complications (23.8%): 5 bladder injuries and 5 vaginal injuries. Thirteen patients had postoperative complications (30.9%), but only two were Clavien grade ⩾3.

Conclusion: The 5-year outcomes of robot-assisted AUS implantation seem to confirm the promising short-term outcomes that have been reported so far, although revision rates increased with time, which warrants further investigation.

机器人女性AUS植入的5年结果:我们的单中心系列42例患者。
近年来,一些初步报道表明,机器人辅助入路可以降低女性压力性尿失禁(SUI)患者人工尿括约肌(AUS)植入术的手术发病率。然而,目前只报道了短期结果。本研究旨在报告机器人辅助AUS植入女性患者的5年结果。患者和方法:2014年1月至2019年9月在同一学术中心接受机器人辅助AUS植入的所有女性患者均纳入回顾性研究。所有在2019年9月之后进行的机器人辅助女性AUS植入都被排除在外,以确保至少5年的随访时间。AUS植入指征为内禀括约肌缺陷所致SUI。主要终点是无解释生存期和无修改生存期。结果:纳入42例患者。中位年龄为66岁(28-84岁),83.8%的患者既往有防尿失禁手术史。中位随访64个月(16-110)后,8例患者在5年时间点之前失去随访。5年估计无修正生存率为89.2,5年估计无解释生存率为88%。需要5个AUS解释(11.9%),6个修订(14.3%)。移植的中位时间为14个月。4例(80%)发生在前18个月,全部发生在前27个月。30例患者(71.42%)完全或改善尿失禁,其中完全失禁率为59.52%,改善失禁率为11.9%。术中并发症10例(23.8%):膀胱损伤5例,阴道损伤5例。13名患者有术后并发症(30.9%),但只有2名患者的Clavien分级大于或小于3。结论:机器人辅助AUS植入的5年结果似乎证实了迄今为止报道的有希望的短期结果,尽管修改率随着时间的推移而增加,这需要进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
39
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Urology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of urology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in urology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest across all areas of urology, including treatment of urological disorders, with a focus on emerging pharmacological therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信